Indian Journal of Rheumatology

REVIEW ARTICLE
Year
: 2006  |  Volume : 1  |  Issue : 2  |  Page : 66--71

TNF blockers and tuberculosis: an Indian concern


VR Tandon1, A Mahajan2, V Khajuria1 
1 Postgraduate Department of Pharmacology & Therapeutics,Government Medical College, Jammu (J & K), India
2 Postgraduate Department of General Medicine, Government Medical College, Jammu (J & K), India

Correspondence Address:
A Mahajan
Postgraduate Department of General Medicine, Government Medical College, Jammu (J & K)
India

Reactivation of latent tuberculosis (TB) with TNF blockers is a cause of concern particularly in developing countries like India, which has a high burden of TB infection. Although etanercept and infliximab are available in India, pub- lished data on Indian experience are scant. Limited data indicate that risk of reactivation of TB is substantially increased. With the growing use of these agents in India inspired by encouraging results in various rheumatic condi- tions a rise in cases of TB is expected. At present, no guidelines exist in India with regard to treatment of latent TB. Indian rheumatologists must adopt a rational approach when treating rheumatic diseases with TNF blockers.


How to cite this article:
Tandon V R, Mahajan A, Khajuria V. TNF blockers and tuberculosis: an Indian concern .Indian J Rheumatol 2006;1:66-71


How to cite this URL:
Tandon V R, Mahajan A, Khajuria V. TNF blockers and tuberculosis: an Indian concern . Indian J Rheumatol [serial online] 2006 [cited 2019 Dec 12 ];1:66-71
Available from: http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2006;volume=1;issue=2;spage=66;epage=71;aulast=Tandon;type=0